These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 27528699)

  • 1. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.
    Rogers LM; Mott SL; Smith BJ; Link BK; Sahin D; Weiner GJ
    Clin Cancer Res; 2017 Feb; 23(4):954-961. PubMed ID: 27528699
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
    Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
    J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD).
    Fritsche LG; Lauer N; Hartmann A; Stippa S; Keilhauer CN; Oppermann M; Pandey MK; Köhl J; Zipfel PF; Weber BH; Skerka C
    Hum Mol Genet; 2010 Dec; 19(23):4694-704. PubMed ID: 20843825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of copy number variation in the regulation of complement activation locus to development of age-related macular degeneration.
    Schmid-Kubista KE; Tosakulwong N; Wu Y; Ryu E; Hecker LA; Baratz KH; Brown WL; Edwards AO
    Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5070-9. PubMed ID: 19553609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
    Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
    Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.
    Dalle S; Reslan L; Besseyre de Horts T; Herveau S; Herting F; Plesa A; Friess T; Umana P; Klein C; Dumontet C
    Mol Cancer Ther; 2011 Jan; 10(1):178-85. PubMed ID: 21220500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy.
    Zhu L; Zhai YL; Wang FM; Hou P; Lv JC; Xu DM; Shi SF; Liu LJ; Yu F; Zhao MH; Novak J; Gharavi AG; Zhang H
    J Am Soc Nephrol; 2015 May; 26(5):1195-204. PubMed ID: 25205734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copy number variation in the complement factor H-related genes and age-related macular degeneration.
    Kubista KE; Tosakulwong N; Wu Y; Ryu E; Roeder JL; Hecker LA; Baratz KH; Brown WL; Edwards AO
    Mol Vis; 2011; 17():2080-92. PubMed ID: 21850184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.
    Zipfel PF; Edey M; Heinen S; Józsi M; Richter H; Misselwitz J; Hoppe B; Routledge D; Strain L; Hughes AE; Goodship JA; Licht C; Goodship TH; Skerka C
    PLoS Genet; 2007 Mar; 3(3):e41. PubMed ID: 17367211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
    Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
    N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.
    Charbonneau B; Maurer MJ; Fredericksen ZS; Zent CS; Link BK; Novak AJ; Ansell SM; Weiner GJ; Wang AH; Witzig TE; Dogan A; Slager SL; Habermann TM; Cerhan JR
    Am J Hematol; 2012 Sep; 87(9):880-5. PubMed ID: 22718493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration.
    Ansari M; McKeigue PM; Skerka C; Hayward C; Rudan I; Vitart V; Polasek O; Armbrecht AM; Yates JR; Vatavuk Z; Bencic G; Kolcic I; Oostra BA; Van Duijn CM; Campbell S; Stanton CM; Huffman J; Shu X; Khan JC; Shahid H; Harding SP; Bishop PN; Deary IJ; Moore AT; Dhillon B; Rudan P; Zipfel PF; Sim RB; Hastie ND; Campbell H; Wright AF
    Hum Mol Genet; 2013 Dec; 22(23):4857-69. PubMed ID: 23873044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab.
    Nozawa A; Ozeki M; Hori T; Kawamoto N; Hirayama M; Azuma E; Fukao T
    J Pediatr Hematol Oncol; 2018 Nov; 40(8):e544-e546. PubMed ID: 28991129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.
    Bernabéu-Herrero ME; Jiménez-Alcázar M; Anter J; Pinto S; Sánchez Chinchilla D; Garrido S; López-Trascasa M; Rodríguez de Córdoba S; Sánchez-Corral P
    Mol Immunol; 2015 Oct; 67(2 Pt B):276-86. PubMed ID: 26163426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.
    Abarrategui-Garrido C; Martínez-Barricarte R; López-Trascasa M; de Córdoba SR; Sánchez-Corral P
    Blood; 2009 Nov; 114(19):4261-71. PubMed ID: 19745068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.